Lyndra Therapeutics
2015
FOUNDED
PRIVATE
STATUS
51-60
EMPLOYEES
Grant
LATEST DEAL TYPE
$13M
LATEST DEAL AMOUNT
16
INVESTORS
Description
Developer of a novel therapeutic platform designed to sustain extended drug release in oral dosage form. The company's platform helps in the linear drug release of small molecules and peptides for seven days or more from each orally administered capsule, enabling physicians to improve patient care by improving therapeutic efficacy, thereby reducing side effects and generating cost-savings.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
- 65 Grove Street
- Suite 301
- Watertown, MA 02472
- United States
+1 (857) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Lyndra Therapeutics’s full profile, request a free trial.
Lyndra Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 08-Nov-2018 | $13M | 000.00 | Completed | Startup | |
| 4. Early Stage VC (Series B) | 11-Feb-2019 | 000.00 | 000.00 | Completed | Startup | |
| 3. Early Stage VC (Series A) | 19-Apr-2017 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Grant | 01-Jan-2017 | $1.27M | Completed | Startup | ||
| 1. Grant | 01-Jan-2016 | $300K | Completed | Startup |
Lyndra Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Lyndra Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 (00000) 000 | 01-May-2018 | 00000 0000000 | Pharmaceuticals | 000 00000000 00 |
Lyndra Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| FujiFilm | Corporation | Minority | 000 0000 | 000000 0 | ||
| Gates Family Foundation | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Gilead Sciences | Corporation | Minority | 000 0000 | 000000 0 | ||
| Hopu Investment Management | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Orient Life | Corporation | Minority | 000 0000 | 000000 0 |
Lyndra Therapeutics Executive Team (12)
8 Former Executives
You’re viewing 4 of 12 executives. Get the full list »Lyndra Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Catherine Reynolds | Lyndra Therapeutics | Chairman of the Board | 000 0000 | |
| Edmund Harrigan MD | Self | Board Member | 000 0000 | |
| Giovanni Traverso Ph.D | Lyndra Therapeutics | Co-Founder & Board Member | 000 0000 | |
| Patricia Hurter | Lyndra Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 | |
| Robert Langer Ph.D | Lyndra Therapeutics | Co-Founder & Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 7 board members. Get the full list »